# Safety and Efficacy of KPI-121 in Subjects With DED

> **NCT03616899** · PHASE3 · COMPLETED · sponsor: **Kala Pharmaceuticals, Inc.** · enrollment: 901 (actual)

## Conditions studied

- Kerato Conjunctivitis Sicca

## Interventions

- **DRUG:** KPI-121 Ophthalmic Suspension
- **DRUG:** Vehicle

## Key facts

- **NCT ID:** NCT03616899
- **Lead sponsor:** Kala Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-10
- **Primary completion:** 2020-02-05
- **Final completion:** 2020-02-05
- **Target enrollment:** 901 (ACTUAL)
- **Last updated:** 2021-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03616899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03616899, "Safety and Efficacy of KPI-121 in Subjects With DED". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03616899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*